Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.55
- Piotroski Score 2.00
- Grade Neutral
- Symbol (ZYME)
- Company Zymeworks Inc.
- Price $14.27
- Changes Percentage (4.31%)
- Change $0.59
- Day Low $13.57
- Day High $14.54
- Year High $17.70
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/05/2025
- Fiscal Year End N/A
- Average Stock Price Target $12.00
- High Stock Price Target $28.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.78
- Trailing P/E Ratio -5.1
- Forward P/E Ratio -5.1
- P/E Growth -5.1
- Net Income $-118,674,000
Income Statement
Quarterly
Annual
Latest News of ZYME
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Halozyme withdraws $2.1 billion buyout offer for German drug developer Evotec
Halozyme Therapeutics withdraws its bid to acquire Evotec SE for 2 billion euros due to lack of engagement. Evotec remains focused on its standalone strategy for growth and profitability, despite inte...
By Yahoo! Finance | 1 day ago -
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery
Halozyme proposed a non-binding takeover of Evotech SE at 11 euros a share, valued at €2 billion. The combined company aims for $2 billion in revenue by 2025, creating a unique pharma services compa...
By MarketWatch | 5 days ago -
ArcticZymes Technologies ASA (FRA:B4V) Q3 2024 Earnings Call Highlights: Navigating Challenges ...
ArcticZymes faces challenges in a tough macroeconomic climate, impacting smaller gene and cell therapy biotechs. The company plans strategic investments led by new VP of Sales to accelerate market pen...
By Yahoo! Finance | 2 weeks ago
